Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Celldex Therapeutics Inc

CLDX ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Mid Cap Analyst: BUY

Last Close

$41.95

▼ -1.55%

Market Cap $3.29B · Vol 258.97K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$3.29B

Mid Cap

Div Yield

N/A

EPS Growth

-8.05%

YoY

RSI (14)

72.71

Momentum

Beta

0.86

vs Market

52W High

$45.13

7.05% below

52W Low

$20.40

105.64% above

Volume

258.97K

Avg 322.81K

P/B

3.43

Price-to-book

ROE

-40.62%

Return on equity

Free Float

99.24%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Celldex Therapeutics Inc (CLDX) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does CLDX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+0.58%

+9.90%

+29.28%

+82.39%

YTD

+54.46%

+68.20%

+33.47%

-4.05%

Financials & Valuation

TTM · Annual

Total Revenue	$1.55M
Net Income	$-258,757,000.00
Revenue Growth (YoY)	-96.99%
Gross Margin	100.00%
Operating Margin	-18,599.81%
Net Profit Margin	-16,748.03%
ROE	-40.62%
ROA · ROIC	-37.63% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	1,167.65
P/B	3.43
P/FCF	N/A
EPS Growth	-8.05%
Outstanding Shares	78.53M

Technical Indicators

50-Day SMA	$36.33
200-Day SMA	$30.39
RSI (14)	72.71
Beta	0.86
52-Week High	$45.13
52-Week Low	$20.40

Volume Today	258.97K
Avg Daily Volume (30D)	322.81K
Relative Volume	0.80x
Volatility (10D)	44.73
Volatility (30D)	44.07
Free Float	99.24%

Analyst Consensus

BUY

Current Price $41.95

Mean Target $58.07

52W Low$20.40 52W High$45.13

Current

Target

$20.40 $45.13

Current Analyst target

+38.42% upside potential · 14 analysts

Identifiers

ExchangeNasdaq

FIGIBBG001S7QN20

ISINUS15117B2025

CountryUnited States of America

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateNov 9, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG -1.78% RVMD Revolution Medicines Inc +0.85% ONC BeOne Medicines AG -2.40% 068270.KS Celltrion Inc -0.50% ABVX Abivax SA -2.05%

Company Profile

Celldex Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases. Its Barzolvolimab (CDX-0159) is a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is being studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis, Atopic Dermatitis and Eosinophilic Esophagitis. The Company’s bispecific platform includes CDX- 622. The CDX- 622 is a bispecific candidate for inflammatory diseases.